0.00Open0.00Pre Close0 Volume0 Open Interest3.00Strike Price0.00Turnover0.00%IV-66.27%PremiumDec 20, 2024Expiry Date5.90Intrinsic Value100Multiplier4DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma1.51Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Emergent BioSolutions Stock Discussion
Emergent BioSolutions Receives $50 Million Contract Option from BARDA to Procure Doses of CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted)
Emergent BioSolutions (NYSE: EBS) has received a $50 million contract option from BARDA for its CYFENDUS® anthrax vaccine. The deliveries are scheduled between now and April 2025. This follows a previous $30 million contract modification for the same vaccine. CYFENDUS®, FDA-approved in July 2023, is a two-dose anthrax vacci...
Just
Emergent BioSolutions Receives $50 Million Contract Option From Barda to Procure Doses of Cyfendus® (Anthrax Vaccine Adsorbed, Adjuvanted
Emergent BioSolutions Inc - Cyfendus Vaccine Deliveries Expected to Complete by April 2025
$Synopsys (SNPS.US)$ $Futu Holdings Ltd (FUTU.US)$ $IonQ Inc (IONQ.US)$
No comment yet